*Rhodococcus*, a gram-positive coccobacillus, has been isolated from water, soil, and the manure of herbivores. It is a facultative intracellular pathogen that survives in host macrophages. Immunosuppressive medications that compromise cell-mediated immunity can predispose to infection ([@R1],[@R2]).

Our knowledge of disease characteristics among transplant recipients is limited to case reports ([@R3]--[@R8]). With the increase in organ transplantation and improved survival of transplant recipients, the incidence of disease will likely increase in the coming years. In this study, we sought to describe characteristics, risk factors, and outcomes of *Rhodococcus* infection among solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients in the United States.

The Study
=========

We conducted a case--control study at 8 US medical centers during January 2000--December 2012. The study was approved by appropriate Institutional Review Boards. Case-patients were those with clinical or radiographic features of infection and positive culture results for *Rhodococcus* spp. Identification of the organism was performed by using biochemical methods at microbiology laboratories of participating institutions. At the discretion of laboratory staff, identification was confirmed by using 16S rRNA sequencing.

Controls received a similar organ within 3 months before or after the index case-patient at the same center and did not show *Rhodococcus* infection. Each case-patient was matched with 2 controls. Allogeneic and autologous HSCT recipients were matched to recipients of the same type.

We used descriptive statistics to summarize results for the cohort. Conditional logistic regression was used to evaluate risk factors for infection. Factors associated with disease less than the 0.10 significance level for univariate analysis were included in the multivariate model. Statistical software Stata/SE version 13.1 (StataCorp LP, College Station, TX, USA) was used.

We identified 18 patients with *Rhodococcus* spp. infection ([Table 1](#T1){ref-type="table"}). Mean age was 55 (range 3--78) years. Six patients underwent HSCT (5 allogeneic, 1 autologous) and 12 SOT (4 heart, 4 lung, 3 kidney, 1 liver). Median time from transplant to infection was 5 (range 2--54) for HSCT recipients and 28 (range 3--237) months for SOT recipients. Infection occurred within the first year posttransplant for half of the patients. Five (39%) of 13 patients were living on a farm or had known contact with horses; exposure history was unknown for 5 patients.

###### Clinical characteristics, treatment, and outcome for 18 patients infected with *Rhodococcus* spp, United States\*

  Patient age, y/sex   Residence       Transplant, underlying disease                     Time from transplant to infection   Clinical feature                                                       Lung pathology                                                        Immunosuppression at infection    Antimicrobial drug treatment                                                                     Treatment duration   Outcome at 90 d†
  -------------------- --------------- -------------------------------------------------- ----------------------------------- ---------------------------------------------------------------------- --------------------------------------------------------------------- --------------------------------- ------------------------------------------------------------------------------------------------ -------------------- --------------------------------------------
  76/M                 Wisconsin       Kidney, obstructive uropathy                       4 y                                 Pneumonia (productive cough, chest pain)                               Chronic inflammation and reactive changes                             Tacrolimus, prednisone            Ertapenem, levofloxacin → moxifloxacin                                                           12 mo                Partial response
  57/F                 Iowa            Heart, ischemic cardiomyopathy                     5 mo                                Catheter-associated bacteremia                                         NT                                                                    Sirolimus, MMF, prednisone        Vancomycin, levofloxacin → levofloxacin                                                          7 mo                 Complete response
  76/M                 Minnesota       Heart, ischemic cardiomyopathy                     20 y                                Pacemaker pocket wound infection                                       NT                                                                    Cyclosporine, MMF, prednisone     TMP/SMX                                                                                          2 mo                 Complete response
  59/F                 Massachusetts   Double lung, usual interstitial pneumonia          8 mo                                Bacteremia                                                             NT                                                                    Cyclosporine, prednisone          Vancomycin → azithromycin                                                                        60 mo                Complete response
  45/M                 Massachusetts   Double lung, lymphangiolyomatosis                  5 y                                 Pneumonia (fever, dyspnea), bacteremia                                 NT                                                                    Tacrolimus, MMF, prednisone       Vancomycin, meropenem → azithromycin, rifampin                                                   8 mo                 Unknown response
  78/F                 Massachusetts   Kidney, diabetic nephropathy                       7 y                                 Pneumonia (productive cough)                                           Small chronic granulomas admixed with reactive bronchial cells        Tacrolimus, MMF, prednisone       Moxifloxacin → doxycycline                                                                       14 mo                Stable disease
  53/M                 Michigan        Heart, ischemic cardiomyopathy                     10 mo                               Pneumonia (cough), bacteremia                                          NT                                                                    Tacrolimus, MMF, prednisone       Vancomycin → levofloxacin, azithromycin                                                          5 mo                 Partial response
  54/M                 Michigan        Kidney, glomerulopathy                             4 mo                                Pneumonia (cough)                                                      NT                                                                    Tacrolimus, MMF, prednisone       Meropenem, azithromycin, meropenem                                                               3 mo                 Partial response
  68/M                 Florida         Heart, ischemic cardiomyopathy                     3 mo                                Pneumonia (fever)                                                      NT                                                                    Tacrolimus, MMF                   Vancomycin, imipenem, TMP/SMX → imipenem, ciprofloxacin                                          11 mo                Partial response
  53/M                 Florida         Liver, alcoholic cirrhosis                         34 mo                               Catheter-associated bacteremia                                         NT                                                                    Sirolimus, MMF                    Vancomycin, ceftriaxone                                                                          3 mo                 Complete response
  67/F                 Pennsylvania    Left lung, idiopathic pulmonary fibrosis           5 y                                 Pneumonia (cough, dyspnea)                                             NT                                                                    Tacrolimus, MMF, prednisone       Vancomycin, azithromycin                                                                         2 mo                 Complete response
  51/M                 Nebraska        Double lung, scleroderma with pulmonary fibrosis   22 mo                               Pneumonia (fever, cough, dyspnea, chest pain)                          NT                                                                    Tacrolimus, MMF, prednisone       Minocycline, azithromycin → azithromycin, linezolid                                              6 mo                 Partial response
  14/M                 California      Allogeneic HSCT, acute myeloid leukemia            6 mo                                Catheter-associated bacteremia                                         NT                                                                    Tacrolimus, prednisone            Linezolid                                                                                        2 wk                 Complete response
  61/M                 Mississippi     Allogeneic HSCT, chronic lymphocytic leukemia      54 mo                               Pneumonia (fever, dyspnea), bacteremia                                 Acute pulmonary inflammation                                          Prednisone                        Meropenem, tigecycline → ertapenem, TMP/SMX, tigecycline                                         6 mo                 Stable response, disease relapse at 9 mo
  65/F                 Texas           Allogeneic HSCT, follicular lymphoma               8 mo                                Pneumonia                                                              Focal tissue, eosinophilia, and Masson bodies; organizing pneumonia   None                              Gatifloxacin, azithromycin                                                                       2 mo                 Complete response
  3/M                  Texas           Autologous HSCT, neuroblastoma                     2 mo                                Bacteremia                                                             NT                                                                    None                              Vancomycin, gatifloxacin                                                                         1 mo                 Complete response
  63/M                 Texas           Allogeneic HSCT, acute myeloid leukemia            4 mo                                Catheter-associated bacteremia                                         NT                                                                    Tacrolimus, prednisone for GVHD   Vancomycin                                                                                       1 mo                 Complete response
  53/F                 Texas           Allogeneic HSCT, chronic myelogenous leukemia      4 mo                                Pneumonia (fever, dyspnea, productive cough, chest pain), bacteremia   NT                                                                    Sirolimus for GVHD                Tigecycline, TMP/SMX, piperacillin/tazobactam → levofloxacin, TMP/SMX, piperacillin/tazobactam   2 wk                 Died of respiratory failure/ARDS at day 13

\*ARDS, acute respiratory distress syndrome; GVHD, graft-versus-host disease; MMF, mycophenolate mofetil; NT, not tested; TMP/SMX, trimethoprim/sulfamethoxazole; →, change in treatment regimen. †Outcome (response to treatment) was categorized as complete (resolution of all attributable signs, symptoms, and radiographic abnormalities); partial (clinical improvement and \>50% improvement in radiographic abnormalities); stable (no improvement in clinical manifestations and \<50% improvement in radiographic findings); or failure (deterioration of condition or death).

Median time to diagnosis after onset of symptoms was 20 (range 2--67) days. This median was determined mainly by the time that the patient sought medical attention and the time of clinical specimen collection. At the time of diagnosis, 3 (17%) patients were managed in outpatient settings, 12 (67%) in inpatient wards, and 3 (17%) in intensive care units.

The predominant infections were pneumonia (61%, 11/18) and bacteremia (56%, 10/18). Bacteremia was secondary to pneumonia for 4 patients and catheter-associated for 4 patients. Fever occurred in half of the patients. Patients with pneumonia had dyspnea (45%, 5/11), cough (70%, 7/10), sputum production (20%, 2/10), and chest pain (30%, 3/10). None had hemoptysis. Lung disease was infiltrative in 8/11 (73%) patients, nodular in 8/11 (73%), and cavitary in 2/11 (18%). Median neutrophil count at diagnosis was 4,133/mm^3^ (range 532--16,468/mm^3^), and median lymphocyte count was 705/mm^3^ (range 90--3,350/mm^3^). Species identification was performed for 9 isolates (8 *R. equi* and 1 *R. corynebacterioides*). We found no significant difference in incidence of preceding opportunistic infection between SOT and HSCT recipients (33% vs. 50%; p = 0.62).

Infected patients were matched with 36 controls. Univariate analysis showed that type of immunosuppression, augmented immunosuppression, increased levels of tacrolimus or cyclosporine, and trimethoprim/sulfamethoxazole (TMP/SMX) prophylaxis were not associated with infection. Multivariate analysis showed that diabetes mellitus (p = 0.041) and recent opportunistic infection (p = 0.045) were independently associated with infection ([Table 2](#T2){ref-type="table"}).

###### Univariate analysis of risk factors associated with *Rhodococcus* infection in solid organ and hematopoietic stem cell transplant recipients, United States\*

  Variable                                 Case-patients, n = 18   Control patients, n = 36   Univariate OR (95% CI)   p value
  ---------------------------------------- ----------------------- -------------------------- ------------------------ ---------
  Mean age, y (range)                      55 (3--78)              50 (2--78)                 1.05 (0.99--1.11)        0.13
  Male sex                                 12/18 (66.7)            22/36 (61.1)               1.21 (0.42--3.45)        0.72
  White race                               15/18 (83.3)            23/36 (63.9)               3.17 (0.65--15.43)       0.15
  Diabetes mellitus†                       9/18 (50.0)             6/34 (17.6)                9.90 (1.20--81.62)       0.03
  Chronic kidney disease‡                  3/16 (18.8)             5/35 (14.3)                1.15 (0.19--7.03)        0.88
  Immunosuppressant                                                                                                    
  Tacrolimus                               10/18 (55.6)            25/35 (71.4)               0.15 (0.02--1.39)        0.10
  Sirolimus                                3/18 (16.7)             2/35 (5.7)                 4.65 (0.46--46.89)       0.19
  Mycophenolate mofetil                    10/18 (55.6)            18/35 (5.4)                1.36 (0.20--9.0)         0.75
  Prednisone                               13/18 (72.2)            25/35 (71.4)               1.00 (0.25--4.0)         1.00
  Cyclosporine                             2/18 (11.1)             3/35 (8.6)                 2.00 (0.13--31.98)       0.62
  Increased calcineurin inhibitor level§   2/13 (15.4)             4/32 (13.3)                1.20 (0.16--9.20)        0.86
  History of allograft rejection           2/12 (16.7)             1/24 (4.2)                 4.00 (0.36--44.11)       0.26
  Augmented immunosuppression¶             7/18 (38.9)             13/37 (35.1)               1.28 (0.24--6.89)        0.77
  TMP/SMX prophylaxis                      10/18 (55.6)            19/36 (52.7)               1.15 (0.33--4.03)        0.83
  History of opportunistic infection\#     7/18 (38.9)             4/36 (11.1)                10.57 (1.25--89.0)       0.03

\*Values are no. (%) unless otherwise indicated. OR, odds ratio; TMP/SMX, trimethoprim/sulfamethoxazole. †Requiring treatment with oral antidiabetic agent(s) or insulin. ‡Creatinine level \>2 mg/dL. §Tacrolimus \>12 μg/mL or cyclosporine \>250 μg/mL in the preceding 30 days. ¶Use of corticosteroid pulses, alemtuzumab, anti-thymocyte globulin, basiliximab, or rituximab in the 6 months preceding infection. \#Opportunistic infections in case-patients were cytomegalovirus viremia (3) or invasive disease (2), pulmonary aspergillosis (1), and BK polyomavirus--associated hemorrhagic cystitis (1).

All isolates tested were susceptible to vancomycin (5/5), rifampin (5/5), linezolid (9/9), and imipenem (7/7). Fourteen percent (1/7) were susceptible to amoxicillin/clavulanate; 29% (2/7) to ceftriaxone; 55% (6/11) to TMP/SMX; 70% (7/10) to tetracycline or minocycline; 75% (6/8) to azithromycin or clarithromycin; and 80% (4/5) to levofloxacin, moxifloxacin, or gatifloxacin. Four isolates were resistant to penicillin and 1 was resistant to clindamycin.

Most patients received combination treatment with 2--3 antimicrobial drugs ([Table 1](#T1){ref-type="table"}). Most commonly used drugs in the initial regimen were vancomycin, a fluoroquinolone, or a carbapenem. Median duration of treatment was 1 month (range 2 weeks--7 months) for patients with cathether-associated bacteremia and 6 months (range 2--60 months) for patients with all other infections. Immunosuppression was decreased in 44% (7/16). The patient with a pacemaker pocket infection had the device removed.

Median follow-up period was 17 (range 1--84) months. One allogeneic HSCT recipient with *R. equi* pneumonia died of respiratory failure 13 days after diagnosis. He was receiving effective treatment with levofloxacin and TMP/SMX. One allogeneic HSCT recipient with bacteremic cavitary pneumonia who received 6 months of antimicrobial drug treatment had disease relapse (fever, cough, and dyspnea) 9 months after initial presentation. *Rhodococcus* spp. were recovered from bronchoalveolar lavage fluid at relapse. The 4 patients with catheter-associated bacteremia had their catheters removed and did not show relapse.

Conclusions
===========

Our study showed an association between *Rhodococcus* infection and preceding opportunistic infection. This finding suggests that affected patients have a high net state of immunosuppression. Prior cytomegalovirus infection, the most common opportunistic infection in the study, might have had an immunomodulatory effect that made patients more likely to show development of a second opportunistic infection.

Most patients were not neutropenic at diagnosis, consistent with the fact that *Rhodococcus* spp. affect mainly patients with impaired cell-mediated immunity. TMP/SMX prophylaxis did not confer protection, probably because of high resistance rates. Patients did not always have a history of exposure to livestock as previously described ([@R2]). Median time to infection was shorter for HSCT recipients, probably because catheter-associated bacteremia was more common among these patients. Predominantly among SOT recipients, infection occurred late after transplant (\>12 months), and none of the infections were catheter-associated ([@R2]).

For systemic infections, monotherapy might result in emergence of resistance. In a report from Taiwan, 3 of 7 *R. equi* isolates had inherent concomitant resistance to all β-lactams, macrolides, and rifampin ([@R9]). We did not observe this multidrug-resistance pattern. For transplant recipients with systemic infection, we recommend combination treatment with 2--3 antimicrobial drugs (vancomycin, fluoroquinolone, or carbapenem). TMP/SMX and clindamycin should be avoided in empiric treatment regimens because of variable rates of susceptibility. Macrolide antimicrobial drugs, except for azithromycin, decrease the metabolism of cyclosporine, tacrolimus, sirolimus, and everolimus. Conversely, rifampin increases the metabolism of these drugs. These interactions should be considered when treating transplant recipients. *Rhodococcus* spp. can also form adherent biofilms ([@R10]). Thus, removal of central catheters is imperative in the management of infected patients.

We observed only 1 death attributable to infection in an HSCT recipient. This finding differs from an attributable mortality rate of 34.3% in a multicenter study of 67 patients with AIDS (mean CD4 cell count 35/μL) ([@R11]). The higher mortality rate probably reflects the degree of immunosuppression among patients with advanced HIV infection and close clinical monitoring of transplant recipients, which enables timely management. Death and relapse rates in our series were comparable with those in a review of 30 cases ([@R2]).

Our retrospective study had inherent limitations related to collection of data. In the analysis, we included SOT and HSCT recipients who differed in underlying disease states and immunosuppression. The study was also limited by the relatively small number of cases. This limitation was also reflected in wide CIs in risk factor analysis. However, we showed that risk factors for *Rhodococcus* infection were diabetes mellitus and recent opportunistic infection. Outcomes were generally favorable after appropriate and timely treatment.
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